Camostat Efficacy vs. Placebo for Outpatient Treatment of... | NCT04583592

NCT04583592

Status Module

Sponsor/Collaborators Module

Oversight Module

Description Module

Conditions Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Camostat Mesilate	Experimental	Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.	Drug: Camostat Mesilate
Placebo	Placebo Comparator	Participants will receive placebo for 14 days in addition to standard of care treatment.	Drug: Placebo

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Camostat Mesilate	Drug	Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.	Camostat Mesilate

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Disease Progression at Day 28	Disease progression will be defined as the number of participants requiring hospitalization (including emergency room visit) or who die due to any cause within 28 days of randomization.	28 days

Secondary Outcomes

Measure	Description	Time Frame
Survival Rate	The overall survival rate (the number of randomized participants who survive up to Day 15 and Day 28).	Up to Day 15 and Day 28
Time to Fever Resolution	Time (in days) from initiation of study treatment until normalization of fever (≤ 37.2 °C oral or tympanic) and sustained for at least 3 days only assessed in participants who experienced a fever within 1 day of enrollment up to Day 28.

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Adults willing and able to provide informed consent before performing study procedures
Adults ≥18 years of age at time of informed consent
Participants must have written notification of laboratory confirmed COVID-19 infection performed prior to screening, at a local laboratory by RT-PCR or other commercial or public health assay in any specimen; and participants must be randomized within 72 hours of receiving the above notification of laboratory confirmed COVID-19
Have a mild or moderate form of COVID-19 defined as SpO2 > 94% at screening
Participants must have at least 1 of the following risk factors for severe illness
1. Aged 65 years or older
2. Hypertension
3. Diabetes mellitus
4. Chronic lung disease including asthma, chronic obstructive pulmonary disease (COPD), and interstitial lung disease (eg, idiopathic pulmonary fibrosis)
5. Chronic cardiac conditions, including coronary artery disease (CAD), heart failure, congenital heart disease, cardiomyopathy
6. Severe obesity (body mass index [BMI] ≥ 40 kg/m^2)
7. Chronic liver disease, including cirrhosis
Must agree not to enroll in another study of an investigational agent or take any other drug that has been granted Emergency Use Authorization prior to completion of Day 28
If women of childbearing potential (WOCBP) or men whose sexual partners are WOCBP, must be able and willing to use at least 1 highly effective method of contraception during the study and for 90 days after receiving the last dose of study drug

Exclusion Criteria:

Physician makes a decision that trial involvement is not in participants' best interest, or has any condition that does not allow the protocol to be followed safely
Known severe liver disease (eg, Child Pugh score > 12, AST >5 times upper limit)
SaO2/SPO2 ≤94% on room air condition, or the Pa02/Fi02 ratio < 300 mgHg
Known allergic reaction to camostat mesilate or one of its excipients
Known severe renal impairment (estimated glomerular filtration rate ≤30 mL/min/1.73 m^2) or receiving dialysis
Pregnant or breastfeeding, or positive pregnancy test in a predose examination
Receipt of any experimental treatment for COVID-19, including agents with demonstrated or possible direct acting antiviral activity, including, but not limited to, remdesivir, hydroxychloroquine, lopinavir/ritonavir, tocilizumab, or ivermectin, within the 30 days prior to the time of the screening evaluation. No off label use of a drug for COVID 19 is allowed.
History of human immunodeficiency virus infection on highly active antiretroviral therapy (HAART)

Contacts/Locations Module

Facility	Status	City	State	ZIP	Country	Contacts
Palmtree Clinical Research, Inc. (Site 125)		Palm Springs	California	92262	United States
Synergy Healthcare, LLC (Site 124)

References Module

No data available

No data is available for this block.

IPD Sharing Statement Module

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	Camostat Mesilate	Participants will receive camostat mesilate for 14 days in addition to standard of care treatment. Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
FG001

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Annotation Section

No data available

No data is available for this block.

Document Section

Large Document Module

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot	Yes	No	No	Study Protocol	Oct 7, 2020	Dec 9, 2021

Derived Section

Miscellaneous Info Module

Submission Tracking

Condition Browse Module

Intervention Browse Module

Masking Info

The Intent-to-Treat population includes all subjects who were randomized. [Note: Subjects may have more than one risk factor upon entry into study.]

Arm/Group Information

ID	Title	Description
BG000	Camostat Mesilate	Participants will receive camostat mesilate for 14 days in addition to standard of care treatment. Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
BG001	Placebo	Participants will receive placebo for 14 days in addition to standard of care treatment. Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.
BG002	Total	Total of all reporting groups

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age, Customized

Count of Participants

Participants

Title

Denominators

Categories

< 55 years

Title	Measurements
	BG000105 BG00153 BG002158

> or = 55 years

Sex: Female, Male

The Intent-to-Treat population includes all subjects who were randomized.

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Female	BG000108 BG00161 BG002

Ethnicity (NIH/OMB)

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Hispanic or Latino	BG000115 BG00162 BG002

Race (NIH/OMB)

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
American Indian or Alaska Native	BG0002 BG0010 BG002

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Disease Progression at Day 28

Disease progression will be defined as the number of participants requiring hospitalization (including emergency room visit) or who die due to any cause within 28 days of randomization.

The Intent-to-Treat population includes all subjects who were randomized

Posted

Count of Participants

Participants

28 days

ID	Title	Description
OG000	Camostat Mesilate	Participants will receive camostat mesilate for 14 days in addition to standard of care treatment. Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
OG001	Placebo	Participants will receive placebo for 14 days in addition to standard of care treatment. Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.

Units	Counts
Participants	OG000194 OG001101

Title

Denominators

Categories

Title	Measurements
	OG00010 OG0016

Group IDs	Group Description	Statistical Method	Statistical Comment	P-Value	P-Value Comment	Parameter Type	Parameter Value	Dispersion Type	Dispersion Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	CI Lower Limit Comment	CI Upper Limit Comment	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type	Non-Inferiority Comment	Other Analysis Description
OG000 OG001		Chi-squared		0.787	<0.05													Superiority

Secondary

Survival Rate

The overall survival rate (the number of randomized participants who survive up to Day 15 and Day 28).

Posted

Count of Participants

Participants

Up to Day 15 and Day 28

ID	Title	Description
OG000	Camostat Mesilate	Participants will receive camostat mesilate for 14 days in addition to standard of care treatment. Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
OG001	Placebo	Participants will receive placebo for 14 days in addition to standard of care treatment. Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.

Units	Counts
Participants	OG000

Secondary

Time to Fever Resolution

Time (in days) from initiation of study treatment until normalization of fever (≤ 37.2 °C oral or tympanic) and sustained for at least 3 days only assessed in participants who experienced a fever within 1 day of enrollment up to Day 28.

Posted

Median

95% Confidence Interval

Days

Up to 28 days

ID	Title	Description
OG000	Camostat Mesilate	Participants will receive camostat mesilate for 14 days in addition to standard of care treatment. Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
OG001	Placebo	Participants will receive placebo for 14 days in addition to standard of care treatment. Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.

Units	Counts
Participants	OG000

Secondary

Resolution of Viral Shedding

Number of participants with no viral shedding (yes/no) using reverse transcriptase-polymerase chain reaction (RT-PCR) at Day 7, Day 15, and at early termination.

Posted

Count of Participants

Participants

Day 1, Day 7 and Day 15

ID	Title	Description
OG000	Camostat Mesilate	Participants will receive camostat mesilate for 14 days in addition to standard of care treatment. Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
OG001	Placebo	Participants will receive placebo for 14 days in addition to standard of care treatment. Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.

Units	Counts
Participants	OG000

Secondary

Rate of Adverse Events and Serious Adverse Events

Number of participants with Adverse events (AEs) and Serious adverse events (SAEs) of any grade from randomization up to Day 28.

A total of 295 subjects were randomized (2:1) to receive a 2-week course of Camostat (n=194) or placebo (n=101) One participant randomized to the placebo group decided to withdraw before taking the first dose of study drug, and one subject randomized to the placebo group was erroneously given Camostat mesilate (As Treated Population: Camostat mesilate, n=195 and placebo, n=99).

Posted

Count of Participants

Participants

28 days

ID	Title	Description
OG000	Camostat Mesilate	Participants will receive camostat mesilate for 14 days in addition to standard of care treatment. Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
OG001	Placebo	Participants will receive placebo for 14 days in addition to standard of care treatment. Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.

Units	Counts

Secondary

Cumulative Rate of Grade 3 and 4 Adverse Events

Cumulative number of participants with grade 3 and 4 AEs from randomization up to Day 28.

Posted

Count of Participants

Participants

28 days

ID	Title	Description
OG000	Camostat Mesilate	Participants will receive camostat mesilate for 14 days in addition to standard of care treatment. Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
OG001	Placebo	Participants will receive placebo for 14 days in addition to standard of care treatment. Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.

Units	Counts

Secondary

Rate of Discontinuation

Number of participants that discontinued from study due to an AE/SAE (discontinued participants will be followed up to Day 28).

The Intent-to-Treat (ITT) population includes all subjects who were randomized.

Posted

Count of Participants

Participants

28 days

ID	Title	Description
OG000	Camostat Mesilate	Participants will receive camostat mesilate for 14 days in addition to standard of care treatment. Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
OG001	Placebo	Participants will receive placebo for 14 days in addition to standard of care treatment. Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.

Units	Counts
Participants	OG000

Secondary

Laboratory Parameter - Platelet Count

Clinical Laboratory Value of Platelet Count at Day 1 and Day 15

The Intent-to Treat Population includes all subjects who were randomized.

Posted

Mean

Standard Deviation

10^9 platelets/L

Day 1 and Day 15

ID	Title	Description
OG000	Camostat Mesilate	Participants will receive camostat mesilate for 14 days in addition to standard of care treatment. Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
OG001	Placebo	Participants will receive placebo for 14 days in addition to standard of care treatment. Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.

Units	Counts
Participants	OG000

Secondary

Laboratory Parameter - Potassium Level

Clinical laboratory value of Potassium Levels at Day 1 and Day 15

Posted

Mean

Standard Deviation

mmol/L

Day 1 and Day 15

ID	Title	Description
OG000	Camostat Mesilate	Participants will receive camostat mesilate for 14 days in addition to standard of care treatment. Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
OG001	Placebo	Participants will receive placebo for 14 days in addition to standard of care treatment. Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.

Units	Counts
Participants	OG000

Secondary

Laboratory Parameter - Aspartate Aminotransferase (AST)

Clinical laboratory values of Aspartate Aminotransferase (AST) at Day 1 and Day 15

The Intent-to-Treat population includes all subjects who were randomized.

Posted

Mean

Standard Deviation

U/L

Day 1 and Day 15

ID	Title	Description
OG000	Camostat Mesilate	Participants will receive camostat mesilate for 14 days in addition to standard of care treatment. Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
OG001	Placebo	Participants will receive placebo for 14 days in addition to standard of care treatment. Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.

Units	Counts
Participants	OG000

Secondary

Laboratory Parameter - Alanine Aminotransferase (ALT)

Clinical laboratory value of Alanine Aminotransferase (ALT) at Day 1 and Day 15

The Intent-to-Treat population includes all subjects who were randomized.

Posted

Mean

Standard Deviation

U/L

Day 1 and Day 15

ID	Title	Description
OG000	Camostat Mesilate	Participants will receive camostat mesilate for 14 days in addition to standard of care treatment. Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
OG001	Placebo	Participants will receive placebo for 14 days in addition to standard of care treatment. Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.

Units	Counts
Participants	OG000

Secondary

Laboratory Parameter - Alkaline Phosphatase (ALP)

Clinical laboratory value of Alkaline Phosphatase (ALP) at Day 1 and Day 15

The Intent-to-Treat population includes all subjects who were randomized.

Posted

Mean

Standard Deviation

U/L

Day 1 and Day 15

ID	Title	Description
OG000	Camostat Mesilate	Participants will receive camostat mesilate for 14 days in addition to standard of care treatment. Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
OG001	Placebo	Participants will receive placebo for 14 days in addition to standard of care treatment. Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.

Units	Counts
Participants	OG000

Secondary

Laboratory Parameter - Gamma-Glutamyl Transferase (GGT)

Clinical laboratory value of Gamma-Glutamyl Transferase (GGT) at Day 1 and Day 15

The Intent-to-Treat population includes all subjects who were randomized.

Posted

Mean

Standard Deviation

U/L

Day 1 and Day 15

ID	Title	Description
OG000	Camostat Mesilate	Participants will receive camostat mesilate for 14 days in addition to standard of care treatment. Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
OG001	Placebo	Participants will receive placebo for 14 days in addition to standard of care treatment. Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.

Units	Counts
Participants	OG000

Secondary

Vital Signs - Heart Rate

Heart rate at Day 1, Day 7 and Day 15

The Intent-to-Treat population includes all subjects who were randomized.

Posted

Mean

Standard Deviation

Beats/Minute

Day 1, Day 7 and Day 15

ID	Title	Description
OG000	Camostat Mesilate	Participants will receive camostat mesilate for 14 days in addition to standard of care treatment. Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
OG001	Placebo	Participants will receive placebo for 14 days in addition to standard of care treatment. Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.

Units	Counts
Participants	OG000

Secondary

Vital Signs - Blood Pressure

Blood pressure (BP) at Day 1, Day 7 and Day 15

The Intent-to-Treat population includes all subjects who were randomized.

Posted

Mean

Standard Deviation

mmHg

Day 1, Day 7 and Day 15

ID	Title	Description
OG000	Camostat Mesilate	Participants will receive camostat mesilate for 14 days in addition to standard of care treatment. Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
OG001	Placebo	Participants will receive placebo for 14 days in addition to standard of care treatment. Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.

Units	Counts
Participants	OG000

Secondary

Vital Signs - Peripheral Capillary Oxygen Saturation (SpO2)

Peripheral Capillary Oxygen Saturation (SpO2) at Day 1, Day 7 and Day 15

The Intent-to-Treat population includes all subjects who were randomized.

Posted

Mean

Standard Deviation

Percentage of SpO2

Day 1, Day 7 and Day 15

ID	Title	Description
OG000	Camostat Mesilate	Participants will receive camostat mesilate for 14 days in addition to standard of care treatment. Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
OG001	Placebo	Participants will receive placebo for 14 days in addition to standard of care treatment. Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.

Units	Counts
Participants	OG000

Arm/Groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Camostat Mesilate	Participants will receive camostat mesilate for 14 days in addition to standard of care treatment. Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.	1	195	10	195	8	195
EG001	Placebo	Participants will receive placebo for 14 days in addition to standard of care treatment. Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.	0	99	5	99	9	99

Serious Adverse Events

Term	Organ System	Assessment Type	Statistical Information
Myocardial Infarction	Cardiac disorders	Systematic Assessment	EG0001 affected195 at risk EG0010 affected99 at risk
Diarrhea	Gastrointestinal disorders	Systematic Assessment	EG0001 affected195 at risk EG0010 affected99 at risk
Fatigue	General disorders	Systematic Assessment	EG0000 affected195 at risk EG0012 affected99 at risk
Pyrexia	General disorders	Systematic Assessment	EG0001 affected195 at risk EG0010 affected99 at risk
Pneumonia	Infections and infestations	Systematic Assessment	EG0005 affected195 at risk EG0012 affected99 at risk
Oxygen saturation decreased	Investigations	Systematic Assessment	EG0002 affected195 at risk EG0010 affected99 at risk
Delusion	Psychiatric disorders	Systematic Assessment	EG0001 affected195 at risk EG0010 affected99 at risk
Renal Failure	Renal and urinary disorders	Systematic Assessment	EG0001 affected195 at risk EG0010 affected99 at risk
Acute Respiratory Distress Syndrome	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 affected195 at risk EG0010 affected99 at risk
Dyspnea	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 affected195 at risk EG0011 affected99 at risk
Hypoxia	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 affected195 at risk EG0011 affected99 at risk
Pleurisy	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 affected195 at risk EG0010 affected99 at risk
Hypotension	Vascular disorders	Systematic Assessment	EG0001 affected195 at risk EG0010 affected99 at risk

Other Adverse Events

Term	Organ System	Assessment Type	Statistical Information
Abdominal Distension	Gastrointestinal disorders	Systematic Assessment	EG0002 affected195 at risk EG0010 affected99 at risk
Abdominal pain	Gastrointestinal disorders	Systematic Assessment	EG0000 affected195 at risk EG0011 affected99 at risk
Constipation	Gastrointestinal disorders	Systematic Assessment	EG0000 affected195 at risk EG0012 affected99 at risk
Diarrhea	Gastrointestinal disorders	Systematic Assessment	EG0001 affected195 at risk EG0010 affected99 at risk
Gastroesophageal Reflux Disease	Gastrointestinal disorders	Systematic Assessment	EG0001 affected195 at risk EG0010 affected99 at risk
Fatigue	General disorders	Systematic Assessment	EG0001 affected195 at risk EG0010 affected99 at risk
Pyrexia	General disorders	Systematic Assessment	EG0000 affected195 at risk EG0012 affected99 at risk
Renal Failure	Renal and urinary disorders	Systematic Assessment	EG0001 affected195 at risk EG0010 affected99 at risk
Acute Respiratory Distress Syndrome	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 affected195 at risk EG0010 affected99 at risk
Dyspnea	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 affected195 at risk EG0011 affected99 at risk
Pneumonia	Infections and infestations	Systematic Assessment	EG0000 affected195 at risk EG0011 affected99 at risk
Corneal abrasion	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected195 at risk EG0011 affected99 at risk
Gamma-glutamyltransferase increased	Investigations	Systematic Assessment	EG0000 affected195 at risk EG0011 affected99 at risk
Oxygen Saturation Decreased	Investigations	Systematic Assessment	EG0000 affected195 at risk EG0011 affected99 at risk
Decreased apetite	Metabolism and nutrition disorders	Systematic Assessment	EG0001 affected195 at risk EG0010 affected99 at risk
Aguesia	Nervous system disorders	Systematic Assessment	EG0001 affected195 at risk EG0011 affected99 at risk
Anosmia	Nervous system disorders	Systematic Assessment	EG0001 affected195 at risk EG0011 affected99 at risk
Anxiety	Psychiatric disorders	Systematic Assessment	EG0001 affected195 at risk EG0010 affected99 at risk
Insomnia	Psychiatric disorders	Systematic Assessment	EG0001 affected195 at risk EG0010 affected99 at risk
Migraine	Nervous system disorders	Systematic Assessment	EG0001 affected195 at risk EG0010 affected99 at risk
Productive cough	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 affected195 at risk EG0010 affected99 at risk
Pruritus	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0001 affected195 at risk EG0010 affected99 at risk
Arthralgia	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected195 at risk EG0011 affected99 at risk
Hypertension	Vascular disorders	Systematic Assessment	EG0000 affected195 at risk EG0011 affected99 at risk

First MCP Posted Date

ID	Term
D000086382	COVID-19

Ancestor Terms

ID	Term
D011024	Pneumonia, Viral
D011014	Pneumonia
D012141	Respiratory Tract Infections
D007239	Infections
D014777	Virus Diseases
D018352	Coronavirus Infections
D003333	Coronaviridae Infections
D030341	Nidovirales Infections
D012327	RNA Virus Infections
D008171	Lung Diseases
D012140	Respiratory Tract Diseases

ID	Term
C034532	camostat

Title	Measurements
	BG00089 BG00148 BG002137